ABSTRACT
lifestyle. This initiative proposes to generate evidence-based practice needed to translate the notion of precision medicine into clinical practice. Studies have identified a genetic predisposition among AA for insulin resistance, but further studies are necessary to substantiate this claim. The aim of this project is to identify common genetic markers found in AA populations with type 2 diabetes.
METHODS
To identify eligible studies, a search was conducted within the PUBMED database for English language articles published at any point in time. Key words included genome-wide association study, single nucleotide polymorphism(s), African American, African Ancestry, non-Hispanic blacks, type 2 diabetes, diabetes, adult-onset diabetes, and non-insulin dependent diabetes. Reference lists from articles retrieved from search engines were searched by hand.
Initially, the titles and abstracts of all the articles were reviewed to determine eligibility, then the full text of the articles that met eligibility were assessed. Studies included in this review met the following criteria: quantitative study, assessments of type 2 diabetes as opposed to type 1 diabetes, and inclusion of African American population. Studies were included regardless of study type or quality. However, methodological issues were addressed throughout the review in order for the reader to weigh the outcomes of each study accurately.
A manual data extraction tool was used to pull out pertinent data from the articles. The data extracted included the purpose statement, study design, sample characteristics and size, country of origin, journal, findings, and limitations. Then a matrix of all the articles included in the review was developed.
FINDINGS
The total number of articles resulting from the electronic and manual search was 30. After reviewing each article based on duplication and inclusion criteria, the final number of research reports identified was 13 studies, as referenced in [7] . Landberg et al. noted that three of the 32 genome-wide associated search (GWAS)-derived single nucleotide polymorphisms (SNPs) showed nominally significant association with type 2 diabetes in the AA cohort [8] . Two of the replicated SNPs were rs864745 in JAZF1 gene and rs10490072 in BCL11A gene. Additionally, Leak et al. reported that type 2 diabetes was observed among 4 SNPs: rs2021785, rs1609659, rs4814597, and rs2269023, while Long revealed that seven of 29 SNPs examined were associated with type 2 diabetes risk, including rs6769511 of the IGF2BP2 gene, 2 SNPs in the WFS1 gene (rs4689388 and rs1801214), rs7903146 of the TCF7L2 gene, and 3 SNPs in the KCNQ1 gene (rs231362, rs2237892, and rs2237897) [9, 10] . Notably, the association for rs7903146 reached significance in the GWAS. Among SNPs determined by other researchers to be genomewide significant, Palmer et al. found a single SNP, rs7560163, reaching genome-wide significance with 4 other SNPs associated with type 2 diabetesrs7542900, rs4659485, rs2722769, rs7107217; these may represent novel loci that contribute to Type 2 Diabetes [11] .
Although type 2 diabetes affects all ages, genders, and ethnicities, some groups are more vulnerable than others, such as Hispanics, Native Americans, and African Ancestry (AA). More than 13 million non-Hispanic blacks are affected by diabetes in the United States. The risk for diabetes in AA is 77 percent higher than non-Hispanic white Americans [12] . Studies have identified genetic association among AA and type 2 diabetes. For example, Keaton et al. suggested that there are ethnic-specific differences in genetic architecture underlying type 2 diabetes, and that these differences complicate the understanding of how risk allele load impacts disease susceptibility [13] . Cheng et al. noted that there were two potential loci for type 2 diabetes, but concluded that no single gene is sufficient to explain a large portion of the observed population difference in risk of diabetes since there undoubtedly is a complex interplay [14] . Research has shown that AA populations with diabetes mellitus have specific genes that those without the disease do not contain (Table 1 
DISCUSSION
AA have nearly twice the prevalence of type 2 diabetes than European-Americans (EA) [7] . Multiple genome-wide studies have shown that there are SNPs present in AA with the disease when compared to EA as well as SNPs present more often in AA with type 2 diabetes than those without the disease. There are also SNPs that correlate with protecting AA from type 2 diabetes. SNPs that has been shown in more than one study to correlate with a genome-wide significance for type 2 diabetes in AA is rs7903146 [10, 18] . Another SNP found to have genome-wide significance for AA with type 2 diabetes is rs7560163. These and other SNPs found more often in populations with type 2 diabetes should be a focus in personalizing treatments for the disease and serving patients on a case by case basis. For example, patients who carry a gene that correlates with higher risk can be made aware of that risk and learn to improve their lifestyles and dietary habits with the goal of preventing the diagnosis altogether. Alternatively, for individuals who have already developed the disease, those with a particular SNP associated with type 2 diabetes may respond better to a specific treatment regimen over another.
However, there are challenges to personalized medicine that include processing large amounts of data, understanding the overall impact of the various SNPs, correlating genotypes with phenotypes, and understanding how treatments can be optimized based on this information [20] . It is clear that more research needs to be carried out, with consideration of these challenges, to determine which treatment approaches would better serve type 2 diabetes patients with each of the at-risk SNPs. It may be that patients with one SNP are better approached using lifestyle changes while another may require medications and more extensive interventions. There is little to no research published that delves into optimal treatments for each SNP found to correlate significantly with the disease.
There are also ethical concerns over the use of individual genomes being used in personalized medicine [21, 22] . Many people are not comfortable with sharing this private information and have fears of losing confidentiality. Just as subjects participating in genome research need to be assured that they will have complete privacy after consenting, so do patients whose SNPs are used in personalized medicine [22] . The benefits of personalized medicine could be extensive as long as patient confidentiality is not placed at risk. Benefits should not put a patient at-risk for being turned away by insurance companies, for example. Fears such as these were addressed in the Genetic Information Nondiscrimination Act of 2008 [23] . This act protects Americans against discrimination from both insurance companies and employers. Furthermore, consent must be obtained when research involving the genome is used. Researchers must explain how information will be used and indicate how confidentiality will be maintained. Insurance companies may not use genomic information to set premiums or determine eligibility just as employers may not use it to hire, fire, determine salaries, or decide on promotions.
FUTURE PERSPECTIVE
Multiple SNPs have been shown to be correlated with AA at risk for type 2 diabetes. This information may be useful to individuals for understanding risk factors for the disease as well as medical practitioners who are treating these patients. However, most patients with type 2 diabetes or with the hereditary risk, do not know which SNPs they carry that put them at risk. This information could allow people to improve their lifestyles before the disease is in full swing. Another key missing piece is understanding what treatments or preventions may best serve those with a particular SNP. There have been little to no advances made in science toward reaching this goal. Thus, more research is necessary so that links can be made between high-risk genes and receiving the necessary treatment to avoid the condition altogether or reduce the symptoms.
